|
General Information
|
|
|
Product
|
CD21 Antibody
|
|
Description
|
Affinity Purified Complement Receptor Type 2 Antibody N-epitope
|
|
Verified Applications
|
ELISA, IHC, IP, WB
|
|
Host
|
Rabbit
|
|
Species Cross Reactivity
|
Human, Mouse
Predicted: Rat
|
|
Immunogen
|
Synthetic peptide taken within amino acid region 650-700 on human Complement Receptor type 2 isoform X1 protein.
|
|
Accession #
|
NCBI: XP_011507508.1
|
|
Physical Properties
|
|
|
Quantity
|
100 µg
|
|
Volume
|
200 µl
|
|
Concentration
|
0.55-0.75 µg/µl in antibody stabilization buffer
|
|
Form
|
Affinity Purified
|
|
Clonality
|
Polyclonal
|
|
Determinant
|
N-epitope
|
|
Storage
|
-20⁰C for long term storage
|
|
Application Protocol
|
|
DB
|
1:10,000
|
|
ELISA
|
1:10,000
|
| Immunohistochemistry |
1:50-1:150 |
|
Immunoprecipitation
|
1:150
|
|
Western Blot
|
1:500
|
|
Protein
|
|
Uniprot #
|
P20023
|
|
Overview
|
Receptor for complement C3Dd, for the Epstein-Barr virus on human B-cells and T-cells and for HNRPU. Participates in B lymphocytes activation.
|
|
Molecular Function
|
Complement binding; DNA binding; Protein homodimerization activity
|
|
Subcellular Location
|
Membrane; Single-pass type I membrane protein
|
|
Expression
|
Mature B-lymphocytes, T-lymphocytes, pharyngeal epithelial cells, astrocytes and follicular dendritic cells of the spleen.
|
|
Structure
|
Interacts (via Sushi domain 1 and 2) with C3dg.
|
|
Alternative Nomenclature
|
C3DR antibody
CD21 antibody
CD21 antigen antibody
Complement C3d receptor antibody
Complement component (3d/Epstein Barr virus) receptor 2 antibody
Complement component receptor 2 antibody
Cr 2 antibody
CR antibody
CVID7 antibody
EBV receptor antibody
EBV-R antibody
Epstein Barr virus receptor antibody
EVBR antibody
SLEB9 antibody
|
| |
|
CD21 Antibody FITC
CD21 Antibody BIOTIN
CD21 Blocking Peptide
CD21 Positive Control
